News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
286,358 Results
Type
Article (9383)
Company Profile (125)
Press Release (276850)
Multimedia
Podcasts (15)
Webinars (6)
Section
Business (85731)
Career Advice (303)
Deals (14763)
Drug Delivery (36)
Drug Development (27143)
Employer Resources (62)
FDA (8183)
Job Trends (7419)
News (138447)
Policy (11498)
Tag
2024 BioCapital Digital (3)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Biotech Bay Standard (12)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (4)
2024 Genetown Standard (5)
2024 Lone Star Bio Digital (3)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (4)
2025 Lone Star Bio Digital (2)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (1177)
Accelerated approval (1)
Adcomms (1)
Allergies (38)
Alliances (26532)
ALS (45)
Alzheimer's disease (601)
Antibody-drug conjugate (ADC) (62)
Approvals (8281)
Artificial intelligence (181)
Autoimmune disease (7)
Automation (12)
Bankruptcy (77)
Best Places to Work (6741)
BIOSECURE Act (10)
Biosimilars (44)
Biotechnology (80)
Bladder cancer (35)
Brain cancer (14)
Breast cancer (143)
Cancer (1162)
Cardiovascular disease (86)
Career advice (272)
Career pathing (8)
CAR-T (77)
Cell therapy (227)
Cervical cancer (14)
Clinical research (23448)
Collaboration (605)
Compensation (118)
Complete response letters (5)
COVID-19 (731)
CRISPR (21)
C-suite (168)
Cystic fibrosis (39)
Data (1174)
Denatured (13)
Depression (19)
Diabetes (118)
Diagnostics (3225)
Digital health (11)
Diversity (1)
Diversity, equity & inclusion (20)
Drug discovery (68)
Drug pricing (40)
Drug shortages (3)
Duchenne muscular dystrophy (45)
Earnings (28090)
Editorial (7)
Employer branding (4)
Employer resources (53)
Events (44078)
Executive appointments (510)
FDA (8958)
Featured Employer (40)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Frontotemporal dementia (3)
Funding (512)
Gene editing (47)
Generative AI (14)
Gene therapy (144)
GLP-1 (218)
Government (1389)
Grass and pollen (1)
Guidances (27)
Healthcare (9244)
Huntington's disease (4)
IgA nephropathy (13)
Immunology and inflammation (40)
Indications (23)
Infectious disease (799)
Inflammatory bowel disease (63)
Inflation Reduction Act (6)
Influenza (28)
Intellectual property (62)
Interviews (42)
IPO (6260)
IRA (22)
Job creations (1060)
Job search strategy (243)
Kidney cancer (3)
Labor market (8)
Layoffs (110)
Leadership (5)
Legal (2002)
Liver cancer (32)
Lung cancer (172)
Lymphoma (71)
Machine learning (3)
Management (21)
Manufacturing (180)
MASH (17)
Medical device (8906)
Medtech (8908)
Mergers & acquisitions (8902)
Metabolic disorders (237)
Multiple sclerosis (30)
NASH (1)
Neurodegenerative disease (31)
Neuropsychiatric disorders (6)
Neuroscience (850)
NextGen: Class of 2025 (2901)
Non-profit (2347)
Northern California (1090)
Now hiring (3)
Obesity (103)
Opinion (101)
Ovarian cancer (40)
Pain (47)
Pancreatic cancer (42)
Parkinson's disease (80)
Partnered (14)
Patents (129)
Patient recruitment (67)
Peanut (20)
People (26831)
Pharmaceutical (35)
Pharmacy benefit managers (1)
Phase I (6748)
Phase II (9438)
Phase III (8884)
Pipeline (576)
Policy (55)
Postmarket research (825)
Preclinical (2237)
Press Release (48)
Prostate cancer (57)
Psychedelics (4)
Radiopharmaceuticals (166)
Rare diseases (163)
Real estate (2670)
Recruiting (24)
Regulatory (9073)
Reports (20)
Research institute (1193)
Resumes & cover letters (31)
Rett syndrome (2)
RSV (10)
Schizophrenia (33)
Series A (90)
Series B (60)
Service/supplier (8)
Sickle cell disease (23)
Southern California (1010)
Special edition (1)
Spinal muscular atrophy (49)
Sponsored (12)
Startups (1807)
State (1)
Stomach cancer (3)
Supply chain (35)
Tariffs (10)
The Weekly (1)
United States (11612)
Vaccines (214)
Venture capitalists (19)
Weight loss (45)
Women's health (19)
Worklife (7)
Date
Today (70)
Last 7 days (301)
Last 30 days (1463)
Last 365 days (18555)
2025 (5417)
2024 (19362)
2023 (20528)
2022 (25079)
2021 (26277)
2020 (25049)
2019 (23871)
2018 (17984)
2017 (15605)
2016 (14509)
2015 (15941)
2014 (11144)
2013 (9000)
2012 (9701)
2011 (9425)
2010 (7917)
Location
Africa (248)
Alabama (24)
Alaska (4)
Arizona (88)
Arkansas (11)
Asia (19504)
Australia (2477)
California (2683)
Canada (1078)
China (402)
Colorado (145)
Connecticut (169)
Delaware (81)
Europe (44779)
Florida (486)
Georgia (127)
Idaho (23)
Illinois (331)
India (15)
Indiana (214)
Iowa (8)
Japan (104)
Kansas (50)
Kentucky (9)
Louisiana (5)
Maine (27)
Maryland (449)
Massachusetts (2134)
Michigan (118)
Minnesota (227)
Mississippi (1)
Missouri (59)
Montana (23)
Nebraska (12)
Nevada (40)
New Hampshire (43)
New Jersey (1046)
New Mexico (19)
New York (907)
North Carolina (546)
North Dakota (6)
Northern California (1090)
Ohio (116)
Oklahoma (11)
Oregon (19)
Pennsylvania (707)
Puerto Rico (5)
Rhode Island (23)
South America (375)
South Carolina (18)
South Dakota (1)
Southern California (1010)
Tennessee (73)
Texas (451)
Utah (90)
Virginia (75)
Washington D.C. (33)
Washington State (229)
West Virginia (1)
Wisconsin (51)
286,358 Results for "freedom innovations".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
THINK Surgical Announces First Use of Maxx Orthopedics’ Freedom® Total Knee implant with the TMINI® Miniature Robotic System
April 17, 2025
·
3 min read
Press Releases
THINK Surgical Receives FDA 510(k) Clearance to use Freedom® Total Knee, Freedom Titan® Knee, and Freedom Primary PCK® System implants with TMINI® Miniature Robotic System
November 19, 2024
·
3 min read
Press Releases
PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1
February 24, 2025
·
10 min read
Press Releases
Curonix leads the PNS market with expanded MR Labeling for 3T Full-Body MRI Scans for its Freedom® Peripheral Nerve Stimulator (PNS) System
January 30, 2025
·
3 min read
FDA
Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
Freedom Biosciences, Inc. (“Freedom Bio” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it may proceed with its FREE001-TRD-201 study for its lead program, FREE001, a ketamine-based combination therapy for the treatment of treatment-resistant depression (TRD).
April 25, 2024
·
7 min read
Pharm Country
KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”) is pleased to announce data on the impact of the Freedom Infusion System on subcutaneous immunoglobulin (SCIg) therapy for primary immunodeficiency diseases (PIDD) to be presented at the National Home Infusion Association (NHIA) 2024 Conference.
March 18, 2024
·
3 min read
Drug Development
PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
PepGen Inc. (Nasdaq: PEPG) today announced that the first patient has been dosed in its Phase 1 clinical trial, FREEDOM-DM1, evaluating PGN-EDODM1 for the treatment of DM1.
December 18, 2023
·
6 min read
Pharm Country
KORU Medical Systems, Inc. Receives FDA 510(k) Clearance for FREEDOM60® Infusion System With Hizentra® 50 ML Prefilled Syringes
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”) today announced that it received U.S. Food and Drug Administration (FDA) clearance for use of the FREEDOM60® Infusion System with Hizentra® 50 mL prefilled syringes (PFS).
November 7, 2023
·
3 min read
Press Releases
PlasCred Circular Innovations Inc. Announces Alberta Innovates Funding Grant
April 8, 2025
·
6 min read
Pharm Country
KORU Medical Systems, Inc. Announces 510(K) Submission for Freedom60® Infusion System With Hizentra® 50 Ml Prefilled Syringes
KORU Medical Systems, Inc. Announces 510(K) Submission for Freedom60 ® Infusion System With Hizentra ® 50 Ml Prefilled Syringes.
July 10, 2023
·
2 min read
1 of 28,636
Next
